Brian Mayhew Joins Firm – Headlines ELIQUENT’s Expanded Regulatory Policy Service Offerings
ELIQUENT Life Sciences Announces:
Brian Mayhew Joins Firm – Headlines ELIQUENT’s Expanded Regulatory Policy Service Offerings
WASHINGTON, DC – ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced that Brian Mayhew – a recognized leader in regulatory policy – has joined the organization. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline regulatory policy, mitigate risk, and accelerate time-to-market.
“Brian’s unparalleled expertise, coupled with his ability to bridge the gap between industry and regulators, has established him as a thought leader in the regulatory policy space,” said Tim Dietlin, Chief Executive Office, ELIQUENT Life Sciences. “Brian will drive forward-thinking solutions that empower clients to achieve compliance, accelerate product development, and maintain a competitive edge in a complex global market.”
Brian Mayhew brings more than two decades of experience to his role as Executive Vice President of Regulatory Policy at ELIQUENT Life Sciences. Brian’s in-depth understanding of the regulatory landscape is rooted in a diverse career spanning roles in regulated industry and at the U.S. Food and Drug Administration (FDA). His deep understanding of the interplay between regulatory frameworks and corporate strategy positions him as a trusted advisor to clients navigating today’s dynamic regulatory environment.
Brian started his career at the FDA where he served as a policy analyst within the Office of the Commissioner. In this capacity, Brian was involved in a wide range of policy issues, including drug advertising, labelling and promotion, medical device user fees, tobacco regulations, and food safety.
Brian’s extensive professional background includes roles across regulated industry. Immediately prior to joining ELIQUENT, Brian served as Vice President of Regulatory Policy at Alkermes. Brian’s career accomplishments also include roles at Novartis, where he served as Executive Director, Global Regulatory & Development Policy and Merck, where he leveraged his regulatory expertise as Associate Director, Regulatory Policy.
Brian’s leadership extends beyond his corporate and FDA experience. As an active member of the Food and Drug Administration Alumni Association (FDAAA), Brian currently serves as the Treasurer and as a member of the FDAAA Board of Directors. Brian’s involvement underscores his commitment to promoting and advancing the mission of the Agency.
Regulatory Policy Solutions
ELIQUENT’s Regulatory Policy Solutions are designed to support the needs of businesses as they navigate regulatory policies. Our expert team works cross-functionally to assist pharmaceutical and biotechnology companies, medical device manufacturers, patient groups, trade associations, and other stakeholders in communicating effectively about regulatory policy issues and in understanding, implementing, and complying with new or changing regulations, guidances and legislation.
ELIQUENT provides the strategic direction and technical expertise that clients count on as they encounter complex regulatory challenges. Our team of industry-recognized professionals empower clients by anticipating policy shifts and maintaining a competitive advantage in a dynamic regulatory landscape. ELIQUENT’s strategic and technical regulatory policy capabilities include:
- Regulatory Policy Interpretation & Application
ELIQUENT provides unparalleled expertise and strategic insight to organizations navigating emerging regulatory policies and industry trends – ensuring compliance while driving innovation.
- Advocacy & Stakeholder Engagement
Engage with stakeholders and shape policy outcomes with targeted advocacy and engagement solutions. Our approach drives impactful results and ensures your voice leads the conversation.
- Regulatory Intelligence
Stay informed with ELIQUENT’s expert monitoring and analysis of regulatory and market trends. Our expert insights enable smarter decisions and proactive planning for long-term success.
Integrated Solutions – Full-Service Support
ELIQUENT redefines regulatory consulting with a full-service platform that delivers integrated solutions across the product lifecycle. The firm’s unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards. ELIQUENT’s integrated platform of regulatory solutions feature the following integrated service offerings:
- Regulatory Affairs Solutions: From the earliest phases of innovation through regulatory submissions, to post- approval support, ELIQUENT guides companies to approval and beyond.
- Pharmacovigilance & Risk Management Solutions: With an approach that includes both strategic direction and hands-on global support, customized PV solutions empower companies to operate with confidence.
- Quality & Compliance Solutions: Highly specialized compliance experts build customized solutions that equip companies with best- in-class strategic support, technical expertise, and project-based solutions.
- Remediations Solutions: Respected professionals and global experts bring an unmatched level of credibility and trust when interacting with regulators and guiding companies to remediation solutions.
- Talent Solutions: Whether you need a team of one or 100+, ELIQUENT’s talent solutions gives clients the ability to rapidly scale teams to the right size, with the right level of expertise, in the right locations.
About ELIQUENT Life Sciences
ELIQUENT Life Sciences is the fusion of six global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC. ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.